Aptevo Therapeutics Inc stock is traded at $0.4442, with a volume of 521,108. It is down -3.64% in the last 24 hours and down -72.58% over the past month. Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Previous Close:
$0.461
Open:
$0.47
24h Volume:
521,108
Relative Volume:
3.20
Market Cap:
$938.76K
Revenue:
$12.99M
Net Income/Loss:
-$27.83M
P/E Ratio:
-
EPS:
-$203.74
Net Cash Flow:
-$26.98M
1W Performance:
-41.55%
1M Performance:
-72.58%
6M Performance:
-90.41%
1Y Performance:
-98.13%
1-Day Range:
$0.4217$0.47
1-Week Range:
$0.4217$0.77
52-Week Range:
$0.4217$25.65
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
206-838-0500Address
2401 4TH AVE., SEATTLE, WA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS